| Species |
Human |
| Protein Construction |
CD59 (Leu26-Asn102)
Accession # P13987-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
35.73 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD59 regulates complement activation cascade at the final step, inhibiting formation of membrane attack complex (MAC). This protein, being anchored to the cell membrane via glycosyl phosphatidyl inositol (GPI), is expressed ubiquitously on cells which are in contact with body fluids containing components. |
| Synonyms |
CD59; 1F5; HRF-20; HRF20; MAC-IP; MACIP; MEM43; MACIF; MIRL; G344; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
